11-K 1 tm2417608d1_11k.htm FORM 11-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 11-K

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________________ to _____________________

Commission File Number 1-2189

Full title of the plan and the address of the plan, if different from that of the issuer named below:

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

ABBOTT LABORATORIES

100 Abbott Park Road

Abbott Park, Illinois 60064-6049

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN

DECEMBER 31, 2023 AND 2022

C O N T E N T S

Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3

FINANCIAL STATEMENTS

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	5

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	6

NOTES TO FINANCIAL STATEMENTS	7

SUPPLEMENTAL SCHEDULE

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	19

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the “Plan”) as of December 31, 2023 and 2022, the related statement of changes in net assets available for benefits for the year ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for benefits for the year ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2023 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan’s auditor since 2002.

Chicago, Illinois
June 25, 2024

Abbott Laboratories Stock Retirement Plan
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2023 and 2022
(Dollars in thousands)

	2023		2022
Assets
Cash	$	81	$	-
Investments, at fair value		14,271,803		13,132,520
Employer contributions receivable		5,524		-
Notes receivable from participants		94,074		89,059
Accrued interest and dividend income		2,994		2,784
Due from brokers		121,715		108,923

Total assets		14,496,191		13,333,286

Liabilities
Cash overdraft		-		304
Investments sold short, at fair value		116,452		105,823
Accrued investment expenses		301		200
Due to brokers		159		189,038

Total liabilities		116,912		295,365

NET ASSETS AVAILABLE FOR BENEFITS	$	14,379,279	$	13,037,921

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Year ended December 31, 2023
(Dollars in thousands)

Additions
Contributions
Employer	$	205,995
Participant		390,099
Rollovers		57,773

Total contributions		653,867

Investment income
Net appreciation in fair value of investments		1,422,204
Interest and dividends		135,815

Net investment income		1,558,019

Interest income on notes receivable from participants		4,375

Total additions		2,216,261

Deductions
Benefits paid to participants		874,701
Other expenses		202

Total deductions		874,903

NET INCREASE		1,341,358

Net assets available for benefits
Beginning of year		13,037,921

End of year	$	14,379,279

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “IRC”), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7). The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

In general, United States employees of Abbott Laboratories (“Abbott”) and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

Alight Solutions serves as the recordkeeper of the Plan. The Northern Trust Company (“Custodian” or “Trustee”) serves as the Plan’s custodian and trustee.

Contributions and Vesting

Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust (“Trust”). The Trust is administered by the Trustee and an investment committee (the “Committee”).

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate contribute from 2% up to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both. The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

Employer matching contributions to the Plan are made each payroll period based on the participating employee’s eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2023 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who makes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year. An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution. Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

Employer contributions are invested according to the participant’s investment elections.

Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

On January 1, 2013, Abbott separated into two publicly traded companies – Abbott and AbbVie Inc. ("AbbVie"). The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting – Continued

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

		Vesting
Service		percentage
Less than two years		0%
Two years or more		100%

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65. Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in employer contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, (2) pay Plan expenses as deemed appropriate by the Administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2023, forfeitures reduced Abbott’s employer contributions by approximately $4.0 million. Approximately $1.0 million and $938,000 in forfeitures were available at the end of 2023 and 2022, respectively.

Distributions and In-Service Withdrawals

Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum. Participants may elect a direct rollover of their accounts. Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1^st of April following the year the participant reaches age 73 or, if earlier, the 31^st of December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to IRC limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Investment Valuation

The Plan offers a variety of investment options to participants. Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock, mutual funds, REITs and futures contracts - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

Corporate debt, government debt and other - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held. Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region’s market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond’s terms and conditions. Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

Certificate of deposit - Valued at amortized cost, which approximates fair value given the instruments’ short duration of less than 130 days.

Futures contracts

One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy. A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date. Futures contracts are exchange-traded and settle daily. Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract. Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

As of December 31, 2023 and 2022, the Plan held futures contracts with a notional amount of approximately $803,000 and $1.6 million, respectively. Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts. The fair value of these derivative contracts was not material at December 31, 2023 and 2022. Changes in fair value are accounted for as investment income (loss) within net appreciation in fair value of investments and totaled approximately $(125,000) for the year ended December 31, 2023.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Short sales

One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy. Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment. To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer. The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement. The price at such time may be more or less than the price at which the investment was sold by the separately managed account. When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2023 and 2022 (dollars in thousands):

	Basis of Fair Value Measurement
2023	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Assets - Investments:
Common stock	$	5,071,247	$	-	$	-	$	-	$	5,071,247
Mutual funds		112,479		-		-		-		112,479
REITs		25,697		-		-		-		25,697
Collective trust funds		-		-		-		8,074,869		8,074,869
Corporate debt		-		269,066		-		-		269,066
Government debt		-		32,173		-		-		32,173
Private 40-Act mutual funds		-		-		-		676,472		676,472
Other		-		9,800		-		-		9,800
Total investments at fair value	$	5,209,423	$	311,039	$	-	$	8,751,341	$	14,271,803

	Basis of Fair Value Measurement
2023	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Liabilities - Investments sold short:
Government debt	$	-	$	116,452	$	-	$	-	$	116,452
Total investments sold short at fair value	$	-	$	116,452	$	-	$	-	$	116,452

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

	Basis of Fair Value Measurement
	Quoted		Significant
	Prices in		Other		Significant
	Active		Observable		Unobservable		Measured at
2022	Markets		Inputs		Inputs		NAV		Total
Assets - Investments:
Common stock	$	5,310,018	$	-	$	-	$	-	$	5,310,018
Mutual funds		107,725		-		-		-		107,725
REITs		24,887		-		-		-		24,887
Collective trust funds		-		-		-		6,706,991		6,706,991
Corporate debt		-		239,076		-		-		239,076
Government debt		-		260,737		-		-		260,737
Private 40-Act mutual fund		-		-		-		477,645		477,645
Certificate of deposit		-		2,501		-		-		2,501
Other		-		2,940		-		-		2,940
Total investments at fair value	$	5,442,630	$	505,254	$	-	$	7,184,636	$	13,132,520

	Basis of Fair Value Measurement
	Quoted		Significant
	Prices in		Other		Significant
	Active		Observable		Unobservable		Measured at
2022	Markets		Inputs		Inputs		NAV		Total
Liabilities - Investments sold short:
Government debt	$	-	$	105,823	$	-	$	-	$	105,823
Total investments sold short at fair value	$	-	$	105,823	$	-	$	-	$	105,823

Participants are permitted to make redemptions from the Plan’s investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2023 and 2022. In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

	2023
	Fair value (NAV)		Redemption frequency	Redemption notice period	Restrictions
Funds filing as direct filing entity:
Collective trusts	$	8,074,869	Daily	0 - 5 days	--
Funds not filing as direct filing entity:
Private 40-Act mutual funds
Asset-backed securities		29,900	Daily	--	Yes (a)
Corporate fixed income		55,771	Daily	--	Yes (a)
Inflation-indexed bonds		8,031	Daily	--	Yes (a)
International fixed income		22,751	Daily	--	Yes (a)
Mortgage-related securities		30,103	Daily	--	Yes (a)
Municipal fixed income		2,573	Daily	--	Yes (a)
Short-term fixed income		486,796	Daily	--	Yes (a)
U.S. Government securities		40,547	Daily	--	Yes (a)

		676,472
	$	8,751,341

	2022
	Fair value (NAV)		Redemption frequency	Redemption notice period	Restrictions
Funds filing as direct filing entity:
Collective trusts	$	6,706,991	Daily	0 - 5 days	--
Funds not filing as direct filing entity:
Private 40-Act mutual funds
Short-term fixed income		477,645	Daily	--	Yes (a)
	$	7,184,636

(a)

The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or 1% of the respective fund’s net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request, but may take up to seven days.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie stock. Investment fees for mutual funds, REITs, collective trusts, and managed accounts are charged against the net assets of the respective fund. Abbott pays other recordkeeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2023 and 2022 is presented below:

	2023		2022
Abbott common shares, 26,051,349 and 26,635,240 shares, respectively (dollars in thousands)	$	2,867,472	$	2,924,283
Market value per share	$	110.07	$	109.79

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Trustee and shares of the Trustee’s common stock. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2023, the Plan received $54 million in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the Trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

NOTE F - TAX STATUS

The Internal Revenue Service (“IRS”) has determined and informed Abbott by a letter dated April 13, 2022, that the Plan and related Trust are designed in accordance with applicable sections of the IRC. The Plan has been amended since the applicable date of the determination letter. However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2023 and 2022, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits in progress.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE G - RISKS AND UNCERTAINTIES

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

NOTE H - SUBSEQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2023 through the date these financial statements were issued. Other than described below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

As of January 1, 2024, all eligible participants may contribute pre-tax, Roth and after tax contributions up to a total of 50% of eligible earnings (previously capped at 25%), subject to certain limitations.

Effective June 1, 2024, Plan participants who are not actively participating in the Abbott Laboratories Annuity Retirement Plan may receive an annual employer contribution equal to 3% of the participant’s eligible earnings, regardless of whether the participant contributes to the Plan. The 3% annual employer contribution will be made shortly after the end of the Plan year only to the eligible participants who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or who have terminated from employment during that Plan year due to death or qualifying retirement or disability during such Plan year. The annual 3% employer contributions will follow the same vesting schedule as the employer matching contributions, becoming fully vested after two years of credited service under the Plan.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
December 31, 2023
(Dollars in thousands)

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - employer securities
*	ABBOTT LABORATORIES, common shares			$	2,867,472

	Common stock
	5TH 3RD BANCORP COM				811
	ABBVIE INC.				1,969,750
	ACADIA HEALTHCARE CO INC COM				241
	ACUITY BRANDS INC COM				221
	ADT INC DEL COM				50
	ADVANCE AUTO PTS INC COM				125
	AECOM				420
	AES CORP COM				174
	AFFILIATED MANAGERS GROUP INC COM STK				182
	AFFIRM HLDGS INC CL A CL A				382
	AFLAC INC COM				1,684
	AGCO CORP COM				261
	AGILENT TECHNOLOGIES INC COM				263
	AGILON HEALTH INC COM				13
	AIR LEASE CORP CL A CL A				151
	AKAMAI TECHNOLOGIES INC COM STK				610
	ALASKA AIR GROUP INC COM				169
	ALBEMARLE CORP COM				584
	ALBERTSONS COS INC CL A CL A				304
	ALLEGION PLC COMMON STOCK				30
	ALLIANT ENERGY CORP COM				447
	ALLISON TRANSMISSION HOLDING				163
	ALLSTATE CORP COM				1,271
	ALLY FINL INC COM				328
	ALNYLAM PHARMACEUTICALS INC COM				161
	AMC ENTMT HLDGS INC CL A NEW				42
	AMCOR PLC ORD USD0.01				482
	AMDOCS ORD GBP0.01				356
	AMEDISYS INC COM				105
	AMER FINL GROUP INC OH COM STK				300
	AMEREN CORP COM				654
	AMERICAN AIRLINES INC COM USD1				195
	AMERICAN WTR WKS CO INC NEW COM				889
	AMETEK INC NEW COM				1,310
	AMPHENOL CORP NEW CL A				993
	ANSYS INC COM				190
	ANTERO MIDSTREAM CORPORATION				99
	ANTERO RES CORP COM				221
	APA CORP COM				44
	APARTMENT INCOME REIT CORP COM				180
	APPLOVIN CORP COM CL A COM CL A				215
	APTARGROUP INC COM				278
	APTIV PLC COM USD				839
	ARAMARK COM				227
	ARCH CAPITAL GROUP COM STK				787
	ARDAGH METAL PACKAGING SA				2
	ARMSTRONG WORLD INDS INC NEW COM STK				106
	ARROW ELECTR INC COM				233
	ASHLAND INC COM USD0.01				139
	ASPEN TECHNOLOGY INC COM USD0.10				209
	ASSURANT INC COM				308

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	ASSURED GUARANTY LTD COMMON STK				147
	ATMOS ENERGY CORP COM				592
	AUTONATION INC COM				147
	AVANGRID INC COM				80
	AVANTOR INC COM				533
	AVERY DENNISON CORP COM				378
	AVIS BUDGET GROUP INC COM STK				80
	AVNET INC COM				157
	AXALTA COATING SYSTEMS LTD COM USD1.00				232
	AXIS CAPITAL HOLDINGS LTD COM				149
	AZEK CO INC CL A CL A				175
	AZENTA INC COM USD0.01				133
	BAKER HUGHES CO				1,198
	BALL CORP COM				613
	BANK NEW YORK MELLON CORP COM STK				1,388
	BANK OZK COM				184
	BATH & BODY WORKS INC COM USD0.5 WI				343
	BAXTER INTL INC COM				677
	BENTLEY SYS INC CL B CL B				26
	BERKLEY W R CORP COM				488
	BERRY GLOBAL GROUP INC				278
	BEST BUY INC COM STK				456
	BILL HOLDINGS INC COM USD0.00001				289
	BIO RAD LABORATORIES INC CL A CL A				230
	BIOGEN INC COMMON STOCK				1,289
	BIOMARIN PHARMACEUTICAL INC COM				550
	BIO-TECHNE CORP COM				24
	BIRKENSTOCK HOLDING PLC COM NPV				36
	BJS WHSL CLUB HLDGS INC COM				200
	BLOCK H & R INC COM				87
	BLOCK INC				911
	BLUE OWL CAP INC COM CL A				201
	BOK FINL CORP COM NEW				85
	BORG WARNER INC COM				289
	BOSTON BEER INC CL A CL A				8
	BOYD GAMING CORP COM				157
	BRIGHT HORIZONS FA COM USD0.001				164
	BRIGHTHOUSE FINL INC COM				108
	BROADRIDGE FINL SOLUTIONS INC COM STK				138
	BROOKFIELD RENEWABLE CORP CLASS A SUBORDINATE VOTING SHARES WI				133
	BROWN & BROWN INC COM				355
	BROWN FORMAN CORP CL A CL A				19
	BROWN-FORMAN INC CL B NON-VTG COM				75
	BRUNSWICK CORP COM				214
	BUILDERS FIRSTSOURCE INC COM STK				709
	BUNGE GLOBAL SA F COMMON STOCK				504
	BWX TECHNOLOGIES INC COM				201
	C H ROBINSON WORLDWIDE INC COM NEW COM NEW				77
	CABLE ONE INC COM				100
	CACI INTL INC CL A CL A				246
	CAESARS ENTMT INC NEW COM				198
	CAMPBELL SOUP CO COM				287
	CAPRI HOLDINGS LTD COM NPV				196
	CARDINAL HLTH INC				419

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	CARLISLE COMPANIES INC COM				523
	CARLYLE GROUP INC COM				298
	CARMAX INC COM				396
	CARNIVAL CORP COM PAIRED				637
	CARRIER GLOBAL CORPORATION COM USD0.01 WI				1,655
	CARTER INC FORMERLY CARTER HLDGS INC TO 09/13/2003 COM				94
	CASEYS GEN STORES INC COM				302
	CATALENT INC COM				279
	CAVA GROUP INC COM				5
	CBOE GLOBAL MARKETS INC				651
	CBRE GROUP INC CL A CL A				976
	CCC INTELLIGENT SOLUTIONS HLDGS INC COM				79
	CDW CORP COM				62
	CELANESE CORP DEL COM STK				531
	CENTERPOINT ENERGY INC COM				624
	CERTARA INC COM				47
	CF INDS HLDGS INC COM				528
	CHARLES RIV LABORATORIES INTL INC COM				415
	CHEMED CORP NEW COM				84
	CHEMOURS CO COM				163
	CHESAPEAKE ENERGY CORP COM NEW 01/2021				335
	CHURCH & DWIGHT INC COM				83
	CIENA CORP COM NEW				230
	CIN FNCL CORP COM				549
	CINTAS CORP COM				198
	CIRRUS LOGIC INC COM				159
	CITIZENS FINL GROUP INC COM				534
	CLARIVATE PLC				151
	CLEAN HBRS INC COM				305
	CLEARWAY ENERGY INC CL A CL A				28
	CLEARWAY ENERGY INC CL C CL C				79
	CLEVELAND CLIFFS USD0.125				351
	CMS ENERGY CORP COM				584
	CNA FNCL CORP COM				39
	CNH INDUSTRIAL NV				412
	COGNEX CORP COM				249
	COGNIZANT TECH SOLUTIONS CORP CL A				1,327
	COHERENT CORP COM				195
	COINBASE GLOBAL INC COM CL A				1,019
	COLUMBIA BKG SYS INC COM				192
	COLUMBIA SPORTSWEAR CO COM				96
	COM ALCOA CORPORATION COM USD0.01				210
	COMERICA INC COM				255
	COMM BANCSHARES INC COM				223
	CONAGRA BRANDS INC COM USD5				473
	CONCENTRIX CORP				149
	CONS EDISON INC COM				1,090
	CONSTELLATION ENERGY CORPORATION COM NPV WI				1,299
	COOPER				635
	CORE & MAIN INC COM CL A COM CL A				187
	COREBRIDGE FINL INC COM				171
	CORNING INC COM				802
	CORTEVA INC COM USD0.01 WI				1,181
	COSTAR GROUP INC COM				695

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	COTERRA ENERGY INC COM				658
	COTY INC COM CL A COM CL A				162
	CRANE CO NEW COM				196
	CRANE NXT CO COM USD1.00				95
	CREDIT ACCEP CORP MICH COM				117
	CROWN HLDGS INC COM				338
	CULLEN / FROST BANKERS INC COM				223
	CUMMINS INC				1,175
	CURTISS WRIGHT CORP COM				292
	D R HORTON INC COM				1,634
	DARDEN RESTAURANTS INC COM				365
	DARLING INGREDIENTS INC COMSTK				273
	DAYFORCE INC				313
	DELTA AIR LINES INC DEL COM NEW COM NEW				849
	DENTSPLY SIRONA INC COM				261
	DEVON ENERGY CORP NEW COM				1,005
	DIAMONDBACK ENERGY INC COM				956
	DICKS SPORTING GOODS INC OC-COM OC-COM				283
	DISCOVER FINL SVCS COM STK				970
	DOLBY LABORATORIES INC CL A COM STK				177
	DOLLAR TREE INC COM STK				1,024
	DONALDSON INC COM				160
	DOORDASH INC CL A COM USD0.00001 CLASS A				226
	DOVER CORP COM USD1.00				743
	DOXIMITY INC COM USD0.001 CL A				65
	DRIVEN BRANDS HLDGS INC COM				31
	DROPBOX INC CL A CL A				30
	DT MIDSTREAM INC COM USD0.01 WI				184
	DTE ENERGY CO COM				787
	DUN & BRADSTREET HLDGS INC COM				112
	DUPONT DE NEMOURS INC COMMON STOCK				1,222
	DXC TECHNOLOGY CO COM				162
	EAGLE MATLS INC COM				82
	EAST WEST BANCORP INC COM				349
	EASTMAN CHEM CO COM				370
	EBAY INC COM USD0.001				756
	ECHOSTAR				49
	EDISON INTL COM				935
	ELANCO ANIMAL HEALTH INC COM				252
	ELECTR ARTS COM				1,281
	ELEMENT SOLUTION INC COM				179
	EMCOR GROUP INC COM				225
	ENCOMPASS HEALTH CORP COM USD0.01				213
	ENOVIS CORPORATION COM USD0.001				102
	ENTEGRIS INC COM				587
	ENTERGY CORP NEW COM				742
	ENVISTA HLDGS CORP COM				136
	EQT CORP COM				481
	EQUIFAX INC COM				322
	ESAB CORPORATION COM USD0.001 WI				168
	ESSENTIAL UTILS INC COM				312
	ETSY INC COM				151
	EURONET WORLDWIDE INC COM				83
	EVERCORE INC				210

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	EVEREST GROUP LTD				452
	EVERGY INC COM NPV				403
	EVERSOURCE ENERGY COM				745
	EXACT SCIENCES CORP COM				298
	EXELIXIS INC COM STK				68
	EXPEDIA GROUP INC COM USD0.001				193
	EXPEDITORS INTL WASH INC COM				561
	F N B CORP PA COM				172
	F5 INC COM STK NPV				365
	FASTENAL CO COM				321
	FERGUSON PLC ORD GBP0.10				1,290
	FIDELITY NATL FINL INC				459
	FIDELITY NATL INFORMATION SVCS INC COM STK				1,231
	FIRST AMERN FINL CORP COM STK				225
	FIRST CTZNS BANCSHARES INC N C CL A CL A				474
	FIRST HAWAIIAN INC COM				102
	FIRST HORIZON CORPORATION COM				272
	FIRST SOLAR INC COM				634
	FIRSTENERGY CORP COM				692
	FLEETCOR TECHNOLOGIES INC COM				49
	FLOWERS FOODS INC COM				148
	FLOWSERVE CORP COM				187
	FMC CORP COM (NEW)				232
	FORTIVE CORP COM MON STOCK				901
	FORTREA HLDGS INC COM				107
	FORTUNE BRANDS INNOVATIONS INC USD0.01				334
	FOX CORP CL A CL A				254
	FOX CORP CL B CL B				124
	FRESHPET INC COM				94
	FRKLN RES INC COM				295
	FRONTIER COMMUNICATIONS PARENT INC COM NPV				215
	FTI CONSULTING INC COM				186
	GALLAGHER ARTHUR J & CO COM				1,553
	GAMESTOP CORP NEW CL A				162
	GAP INC COM				141
	GARMIN LTD COMMON STOCK				682
	GATES INDL CORP PL COM USD0.01				52
	GEN DIGITAL INC COM USD0.01				370
	GENERAC HLDGS INC COM STK				272
	GENPACT LIMITED				160
	GENTEX CORP COM				264
	GENUINE PARTS CO COM				672
	GINKGO BIOWORKS HOLDINGS INC COM				82
	GLOBAL PMTS INC COM				1,133
	GLOBALFOUNDRIES INC				164
	GLOBE LIFE INC COM				370
	GLOBUS MED INC CL A NEW COM STK				155
	GODADDY INC CL A CL A				213
	GRACO INC COM				296
	GRAND CANYON ED INC COM STK				98
	GRAPHIC PACKAGING HLDG CO COM STK				120
	GROCERY OUTLET HLDG CORP COM				88
	GUIDEWIRE SOFTWARE INC COM USD0.0001				308
	GXO LOGISTICS INC COM				247

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	HALLIBURTON CO COM				897
	HANOVER INS GROUP INC COM				150
	HARLEY DAVIDSON COM USD0.01				164
	HARTFORD FINL SVCS GROUP INC COM				821
	HASBRO INC COM				231
	HASHICORP INC COM USD0.000015 CL A				25
	HAWAIIAN ELEC INDS INC COM				54
	HAYWARD HLDGS INC COM				62
	HEICO CORP NEW CL A CL A				38
	HEICO CORP NEW COM				27
	HENRY SCHEIN INC COMMON STOCK				340
	HERTZ GLOBAL HLDGS INC NEW COM NEW				47
	HESS CORP COM STK				613
	HEWLETT PACKARD ENTERPRISE CO COM				751
	HEXCEL CORP NEW COM				215
	HF SINCLAIR CORPORATION COM USD0.01				277
	HILTON WORLDWIDE HLDGS INC COM NEW				849
	HOLOGIC INC COM				599
	HORMEL FOODS CORP COM				321
	HOULIHAN LOKEY INC CL A CL A				196
	HOWARD HUGHES HLDGS INC COM				99
	HOWMET AEROSPACE INC COM USD1.00 WI				710
	HP INC COM				716
	HUBBELL INC COM				332
	HUNT J B TRANS SVCS INC COM				456
	HUNTINGTON BANCSHARES INC COM				634
	HUNTINGTON INGALLS INDS INC COM				352
	HUNTSMAN CORP COM STK				147
	HYATT HOTELS CORP COM CL A COM CL A				197
	IAC INC COM NEW				134
	ICON PLC COM				678
	ICU MED INC COM				70
	IDACORP INC COM				170
	IDEX CORP COM				522
	ILLUMINA INC COM				535
	INCYTE CORP COM				104
	INFORMATICA INC CL A CL A				39
	INGERSOLL RAND INC COM				1,081
	INGREDION INC COM				248
	INTEGRA LIFESCIENCES HLDG CORP COM DESP				103
	INTERACTIVE BROKERS GROUP INC CL COM				299
	INTERPUBLIC GROUP COMPANIES INC COM				436
	INTL FLAVORS & FRAGRANCES INC COM				715
	INTL PAPER CO COM				434
	INVESCO LTD COM STK USD0.20				225
	IONIS PHARMACEUTICALS INC COM				35
	IPG PHOTONICS CORP COM				112
	IQVIA HLDGS INC COM USD0.01				107
	IRIDIUM COMMUNICATIONS INC COM STK				12
	ITT INC COM				341
	JABIL INC COM USD0.001				204
	JACK HENRY & ASSOC INC COM				281
	JACOBS SOLUTIONS INC COM				564
	JANUS HENDERSON GROUP PLC				141

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	JAZZ PHARMACEUTICALS PLC COM				124
	JEFFERIES FINL GROUP INC COM				255
	JONES LANG LASALLE INC COM STK				308
	JUNIPER NETWORKS INC COM				325
	KARUNA THERAPEUTICS INC COM				41
	KBR INC COM				163
	KELLANOVA COM USD0.25				504
	KEMPER CORP DEL COM				102
	KEYCORP NEW COM				465
	KEYSIGHT TECHNOLOGIES INC COM				726
	KIRBY CORP COM				160
	KKR & CO INC CL A CL A				1,434
	KNIGHT-SWIFT TRANSN HLDGS INC CL A				311
	KOHLS CORP COM				110
	KROGER CO COM				1,032
	KYNDRYL HLDGS INC COM				163
	LAB CORP AMER HLDGS COM NEW				668
	LAMAR ADVERTISING CO NEW CL A CL A				74
	LAMB WESTON HLDGS INC COM USD5				30
	LANDSTAR SYS INC COM				48
	LEAR CORP COM NEW COM NEW				282
	LEGGETT & PLATT INC COM				121
	LEIDOS HLDGS INC COM				511
	LENNAR CORP CL A CL A				1,265
	LENNAR CORP CL B CL B				60
	LENNOX INTL INC COM				495
	LIBERTY BROADBAND CORP COM SER A COM SERA				35
	LIBERTY BROADBAND CORP COM SER C COM SERC				258
	LIBERTY MEDIA CORP DEL COM LIBERTY FORMULA ONE SER A				48
	LIBERTY MEDIA CORP DEL COM LIBERTY FORMULA ONE SER C				423
	LIBERTY MEDIA CORP DEL COM LIBERTY SIRIUSXM SER A				74
	LIBERTY MEDIA CORP DEL COM LIBERTY SIRIUSXM SER C				153
	LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER A				25
	LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER C				60
	LINCOLN ELEC HLDGS INC COM				27
	LINCOLN NATL CORP COM				144
	LITHIA MTRS INC COM CL A				307
	LITTELFUSE INC COM				223
	LIVE NATION ENTERTAINMENT INC				391
	LKQ CORP COM LKQ CORP				440
	LOEWS CORP COM				441
	LOUISIANA-PACIFIC CORP COM				157
	LUCID GROUP INC COM				108
	LUMENTUM HLDGS INC COM				121
	LYONDELLBASELL IND N V COM				851
	M & T BK CORP COM				785
	MACYS INC COM STK				188
	MADISON SQUARE GARDEN SPORTS				117
	MANPOWERGROUP INC				136
	MAPLEBEAR INC COM				5
	MARATHON OIL CORP COM				504
	MARAVAI LIFESCIENCES HLDGS INC CL A				10
	MARKEL GROUP INC				645
	MARRIOTT VACATIONS WORLDWIDE CORP COM				105

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	MARTIN MARIETTA MATLS INC COM				1,063
	MARVELL TECHNOLOGY INC COM				1,782
	MASCO CORP COM				522
	MASTEC INC COM				163
	MATCH GROUP INC NEW COM				35
	MATTEL INC COM STOCK				229
	MC CORMICK & CO INC COM NON-VTG				595
	MDU RES GROUP INC COM				139
	MERCURY SYSTEMS INC				68
	MGIC INVT CORP WIS COM				184
	MGM RESORTS INTERNATIONAL COM				436
	MICROCHIP TECHNOLOGY INC COM				483
	MIDDLEBY CORP COM				271
	MIRATI				111
	MISTER CAR WASH INC COM				23
	MKS INSTRS INC COM				237
	MOHAWK INDS INC COM				189
	MOLINA HEALTHCARE INC COM				327
	MOLSON COORS BEVERAGE COMPANY COM USD0.01 CLASS B				370
	MOSAIC CO/THE				408
	MP MATERIALS CORP COM USD0.0001 CL A				71
	MSA SAFETY INC COM				179
	MSC INDL DIRECT INC CL A COM				165
	MSCI INC COM USD0.01				753
	MURPHY USA INC COM				12
	NASDAQ INC				688
	NATL FUEL GAS CO COM				153
	NCINO INC NEW COM				74
	NCR ATLEOS CORPORATION COM USD0.01 WI				54
	NCR VOYIX CORP COM STK USD0.01				75
	NETAPP INC COM STK				388
	NEW YORK CMNTY BANCORP INC COM				252
	NEW YORK TIMES CO CL A				273
	NEWELL BRANDS INC COM				115
	NEWMARKET CORP COM				118
	NEWS CORP COM CL A				325
	NEWS CORP COM CL B				101
	NEXSTAR MEDIA GROUP INC COMMON STOCK				119
	NISOURCE INC COM				380
	NORDSON CORP COM				522
	NORDSTROM INC COM				73
*	NORTHERN TR CORP COM				599
	NORWEGIAN CRUISE LINE HLDGS LTD COM				222
	NOV INC COM				276
	NRG ENERGY INC COM NEW				406
	NU HOLDINGS LTD				212
	NUCOR CORP COM				1,496
	NUTANIX INC CL A CL A				304
	NVENT ELECTRIC PLC COM USD0.01 WI				336
	NVR INC COM STK USD0.01				651
	OGE ENERGY CORP COM				242
	OKTA INC CL A CL A				448
	OLAPLEX HLDGS INC COM				11
	OLD DOMINION FREIGHT LINE INC COM				94

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	OLD REPUBLIC INTERNATIONAL CORP COM STK USD1				267
	OLIN CORP COM				228
	OLLIES BARGAIN OUTLET HLDGS INC COM				109
	OMNICOM GROUP INC COM				591
	ON SEMICONDUCTOR CORP COM				1,245
	ONEMAIN HLDGS INC COM				192
	ONEOK INC COM STK				1,334
	ORGANON & CO COM				128
	OSHKOSH CORPORATION				244
	OTIS WORLDWIDE CORP COM USD0.01 WI				1,205
	OVINTIV INC COM USD0.01				216
	OWENS CORNING NEW COM STK				454
	PACCAR INC COM				1,732
	PACKAGING CORP AMER COM				498
	PARAMOUNT GLOBAL COM USD0.001 CL A				6
	PARAMOUNT GLOBAL OM USD0.001 CL B				295
	PARKER-HANNIFIN CORP COM				2,036
	PAYCOR HCM INC COM				26
	PENN ENTERTAINMENT INC				135
	PENSKE AUTOMOTIVE GROUP INC COM STK				108
	PENTAIR PLC COM USD0.01				413
	PERFORMANCE FOOD GROUP CO COM				193
	PERRIGO COMPANY LIMITED COM EUR0.001				150
	PETCO HEALTH & WELLNESS CO INC CL A COM				9
	PG& E CORP COM				1,269
	PHILLIPS 66 COM				2,049
	PHINIA INC COM USD0.01 WI				49
	PILGRIMS PRIDE CORP				39
	PINNACLE FINL PARTNERS INC COM				227
	PINNACLE W. CAP CORP COM				282
	PLANET FITNESS INC CL A CL A				112
	PLAYTIKA HLDG CORP COM				1
	PLUG PWR INC COM NEW				82
	POLARIS INC				161
	POPULAR INC COM NEW COM USD6 (POST REV SPLIT)				200
	POST HLDGS INC COM STK				156
	PPG IND INC COM				910
	PPL CORP COM ISIN US69351T1060				692
	PREMIER INC CL A CL A				92
	PRIMERICA INC COM				89
	PRINCIPAL FINL GROUP INC COM STK				659
	PROSPERITY BANCSHARES INC COM				205
	PRUDENTIAL FINL INC COM				1,304
	PTC INC COM				330
	PUB SERVICE ENTERPRISE GROUP INC COM				1,052
	PULTE GROUP INC				763
	PURE STORAGE INC CL A CL A				76
	PVH CORP COM USD1				254
	QIAGEN				347
	QORVO INC COM				382
	QUANTA SVCS INC COM				790
	QUANTUMSCAPE CORP COM USD0.0001 CL A				81
	QUEST DIAGNOSTICS INC COM				535
	QUIDELORTHO CORPORATION				135

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	R1 RCM INC NEW				56
	RALPH LAUREN CORP CL A CL A				200
	RANGE RES CORP COM				246
	RAYMOND JAMES FNCL INC COM STK				731
	RB GLOBAL INC				98
	RBC BEARINGS INC COM				278
	REGAL REXNORD CORPORATION COM STK				338
	REGIONS FINL CORP NEW COM				628
	REINSURANCE GROUP AMER INC COM NEW STK				371
	RELIANCE INC COM NPV				559
	RENAISSANCE RE HLDGS LTD COM				250
	REPLIGEN CORP COM STK USD0.01				193
	REPUBLIC SVCS INC COM				1,178
	REVVITY INC				469
	REYNOLDS CONSUMER PRODS INC COM				51
	RH COM				131
	RIVIAN AUTOMOTIVE INC				538
	RLI CORP COM				144
	ROBERT HALF INC COM USD0.001				314
	ROBINHOOD MKTS INC COM CL A COM CL A				296
	ROCKET COS INC CL A CL A				39
	ROIVANT SCIENCES LTD COM				8
	ROKU INC COM CL A COM CL A				342
	ROSS STORES INC COM				107
	ROYAL CARIBBEAN GROUP COM STK				732
	ROYAL GOLD INC COM STK USD0.01				276
	ROYALTY PHARMA PLC COM CLASS A				362
	RPM INTL INC				397
	RYDER SYS INC COM				174
	S.W. AIRL CO COM				594
	SAIA INC COM STK				357
	SCHNEIDER NATL INC WIS CL B CL B				47
	SCIENCE APPLICATIONS INTL CORP NEW COM				227
	SEABOARD CORP DEL COM				25
	SEALED AIR CORP NEW COM STK				81
	SEI INVTS CO COM				222
	SENSATA TECHNOLOGIES B V HOLDING				196
	SENTINELONE INC CL A COM CL A COM				192
	SERVICE CORP INTL COM				222
	SILGAN HLDGS INC COM				130
	SIRIUS XM HLDGS INC COM				122
	SITEONE LANDSCAPE SUPPLY INC COM				169
	SKECHERS U S A INC CL A CL A ISIN				266
	SKYWORKS SOLUTIONS INC COM				619
	SLM CORP COM				92
	SMITH A O CORP COM				308
	SMUCKER J M CO COM NEW				450
	SNAP-ON INC COM				520
	SOFI TECHNOLOGIES INC COM				321
	SONOCO PROD CO COM				189
	SOTERA HEALTH CO COM				17
	SOUTHWESTERN ENERGY CO COM				247
	SPECTRUM BRANDS HLDGS INC COM USD0.01				96
	SPIRIT AEROSYSTEMS HLDGS INC CL A				103

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	SS&C TECHNOLOGIES HLDGS INC COM				461
	SSR MNG INC				75
	STANLEY BLACK & DECKER INC COM				520
	STATE STR CORP COM				827
	STEEL DYNAMICS INC COM				637
	STERICYCLE INC COM				158
	STERIS PLC ORD USD0.001				754
	STIFEL FINL CORP COM				239
	SUNRUN INC COM				143
	SYNCHRONY FINL COM				545
	SYNOVUS FINL CORP COM NEW COM NEW				190
	T ROWE PRICE GROUP INC				823
	TAKE-TWO INTERACTIVE SOFTWARE INC COM STK USD0.01				918
	TANDEM DIABETES CARE INC COM NEW COM USD0.001(POST REV SPLT)				57
	TAPESTRY INC COM USD0.01				273
	TD SYNNEX CORPORATION COM USD0.001				195
	TECHNIPFMC PLC COM USD1				301
	TELADOC HEALTH INC				123
	TELEDYNE TECHNOLOGIES INC COM				718
	TELEFLEX INC COM				405
	TEMPUR SEALY INTL INC				235
	TENET HEALTHCARE CORP COM NEW .				264
	TERADYNE INC COM				97
	TETRA TECH INC NEW COM				250
	TEXTRON INC COM				543
	TFS FINL CORP COM STK				27
	THOR INDS INC COM STK				209
	TIMKEN CO COM				169
	TOLL BROS INC COM				381
	TOPBUILD CORP COM				383
	TPG PARTNERS LLC CL A COM				70
	TRADEWEB MKTS INC CL A CL A				237
	TRANE TECHNOLOGIES PLC COM USD1				1,354
	TRANSDIGM GROUP INC COM				1,540
	TRANSUNION COM				459
	TRAVEL + LEISURE CO COM USD0.01				53
	TRIMBLE INC COM TRIMBLE INC				453
	TRIPADVISOR INC COM USD0.001				79
	TWILIO INC CL A CL A				371
	TYLER TECHNOLOGIES INC COM STK				146
	TYSON FOODS INC CL A COM (DELAWARE)				517
	UBIQUITI INC COM				3
	UGI CORP NEW COM				179
	U-HAUL HOLDING COMPANY				150
	U-HAUL HOLDING COMPANY				12
	UIPATH INC CL A CL A				76
	UNDER ARMOR INC CL A				58
	UNDER ARMOUR INC CL C COM				57
	UNITED AIRLINES HOLDINGS INC COM USD0.01				466
	UNITED RENTALS INC COM				1,067
	UNITED STS STL CORP NEW COM				372
	UNITED THERAPEUTICS CORP DEL COM STK				343
	UNITY SOFTWARE INC COM				250
	UNIVERSAL DISPLAY CORP COM				169

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	UNUM GROUP				307
	UNVL HEALTH SERVICES INC CL B COM				316
	US FOODS HLDG CORP COM				356
	UWM HLDGS CORP COM USD0.0001 CL A				16
	V F CORP COM				228
	VAIL RESORTS INC COM				251
	VALMONT INDS INC COM				157
	VALVOLINE INC COM				134
	VERISIGN INC COM				600
	VERTIV HOLDINGS LLC COM USD0.0001				528
	VESTIS CORP COM				86
	VIASAT INC COM				113
	VIATRIS INC				448
	VICTORIAS SECRET & CO COM				39
	VIRTU FINL INC CL A CL A				63
	VISTRA CORP COM USD0.01				343
	VONTIER CORP COM USD0.0001 WI				123
	VOYA FINL INC COM				249
	VULCAN MATERIALS CO COM				810
	WABTEC CORP COM				782
	WALGREENS BOOTS ALLIANCE INC COM				648
	WARNER BROS DISCOVERY INC				867
	WATSCO INC COM				369
	WAYFAIR INC CL A CL A				114
	WEBSTER FNCL CORP WATERBURY CONN COM				301
	WEC ENERGY GROUP INC COM				919
	WESCO INTL INC COM				266
	WESTERN ALLIANCE BANCORPORATION COM				246
	WESTERN UNION CO				129
	WESTLAKE CORPORATION COM USD0.01				155
	WESTN DIGITAL CORP COM				587
	WESTROCK CO COM				365
	WEX INC COM				155
	WHIRLPOOL CORP COM				226
	WHITE MOUNTAINS INSURANCE GROUP				128
	WILLIAMS CO INC COM				1,468
	WILLIAMS SONOMA INC COM				387
	WILLIS TOWERS WATSON PLC COM				756
	WILLSCOT MOBILE MINI HLDGS CORP COM				221
	WINTRUST FINL CORP COM				196
	WK KELLOGG CO COM				30
	WOLFSPEED INC COM				187
	WOODWARD INC COM				281
	WYNDHAM HOTELS & RESORTS INC COM				209
	WYNN RESORTS LTD COM				308
	XCEL ENERGY INC COM				1,179
	XP INC COM				268
	XPO INC COM				345
	XYLEM INC COM				826
	YUM BRANDS INC COM				156
	ZEBRA TECHNOLOGIES CORP CL A				397
	ZILLOW GROUP INC COM				106
	ZILLOW GROUP INC COM CLASS C				311
	ZIMMER BIOMET HLDGS INC COM				885

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - continued
	ZIONS BANCORPORATION N A				221
	ZOOM VIDEO COMMUNICATIONS INC CL A CL A				632
	ZOOMINFO TECHNOLOGIES INC COM				93
	Total Common stock				5,071,247

	Mutual fund
	PIMCO ALL ASSET FUND				112,479

	REITs
	1ST INDL RLTY TR INC COM				240
	AGNC INVT CORP COM				221
	AGREE RLTY CORP COM				214
	ALEXANDRIA REAL ESTATE EQUITIES INC COM				752
	AMERICAN HOMES 4 RENT COMMON STOCK				412
	AMERICOLD RLTY TR INC COM				283
	ANNALY CAPITAL MANAGEMENT INC COM NEW COM USD0.01(POST REV SPLT)				332
	AVALONBAY CMNTYS REIT				917
	BRIXMOR PPTY GROUP INC COM				242
	BSTN PPTYS INC				382
	CAMDEN PPTY TR SH BEN INT				356
	COUSINS PPTYS INC				129
	CUBESMART				359
	DIGITAL RLTY TR INC COM				1,405
	EASTGROUP PPTYS INC REIT				289
	EPR PPTYS COM SH BEN INT COM SH BEN INT				125
	EQTY LIFESTYLE PPTYS INC REIT				292
	EQTY RESDNTL EFF 5/15/02				789
	ESSEX PPTY TR REIT				548
	EXTRA SPACE STORAGE INC COM				1,159
	FEDERAL RLTY INVT TR COM USD0.01				289
	GAMING & LEISURE PPTYS INC COM				437
	HEALTHCARE REALTY TRUST INC COM USD0.01 CL A				227
	HEALTHPEAK OP LLC				376
	HIGHWOODS PPTYS INC COM				84
	HOST HOTELS & RESORTS INC REIT				475
	INVITATION HOMES INC COM				720
	IRON MTN INC NEW COM				355
	KILROY RLTY CORP COM				161
	KIMCO REALTY CORPORATION				447
	MEDICAL PPTYS TR INC COM REIT				101
	MID-AMER APT CMNTYS INC COM				540
	NATIONAL STORAGE AFFILIATES TR COM SHS BEN INT COM SHS BEN INT				116
	NET LEASE OFFICE PPTYS COM				9
	NNN REIT INC				271
	OMEGA HEALTHCARE INVS INC REIT				260
	PARK HOTELS & RESORTS INC COM				113
	RAYONIER INC REIT				170
	REALTY INCOME				213
	REALTY INCOME CORP COM				1,437
	REGENCY CTRS CORP COM				418
	REXFORD INDL RLTY INC COM				407
	RITHM CAPITAL CORP				179
	SBA COMMUNICATIONS CORP				847
	SIMON PROPERTY GROUP INC COM				1,253
	STAG INDL INC COM				247

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	REITs - continued
	STARWOOD PROPERTY TRUST INC COM REIT				216
	SUN COMMUNITIES INC COM				443
	UDR INC COM STK				411
	VENTAS INC REIT				689
	VICI PPTYS INC COM				1,138
	VORNADO RLTY TR COM				174
	W P CAREY INC COM				476
	WELLTOWER INC COM REIT				1,673
	WEYERHAEUSER CO COM				879
	Total REITs				25,697

	Collective trust funds
	BLACKROCK INTERNATIONAL MULTI CAP EQUITY FUND				114,279
	CAPITAL GROUP EUROPACIFIC GROWTH TRUST				355,375
	CAPITAL GROUP GROWTH FUND OF AMERICA TRUST				1,091,473
	CAPITAL GROUP WASHINGTON MUTUAL INVESTORS TRUST				343,658
	GW&K SMALL-MID CAP CORE EQUITY FUND				163,769
*	NORTHERN TRUST COLLECTIVE ACWI ex-U.S. INDEX FUND				147,105
*	NORTHERN TRUST COLLECTIVE SHORT TERM INVESTMENT FUND				9,767
	SSGA RUSSELL SMALL/MID CAP INDEX FUND CLASS K				791,167
	SSGA S&P 500 INDEX FUND CLASS K				1,828,282
	SSGA U.S. BOND INDEX FUND CLASS K				143,794
	SSGA TARGET RETIREMENT 2020				208,428
	SSGA TARGET RETIREMENT 2025				406,148
	SSGA TARGET RETIREMENT 2030				511,724
	SSGA TARGET RETIREMENT 2035				489,296
	SSGA TARGET RETIREMENT 2040				407,718
	SSGA TARGET RETIREMENT 2045				354,113
	SSGA TARGET RETIREMENT 2050				284,105
	SSGA TARGET RETIREMENT 2055				179,847
	SSGA TARGET RETIREMENT 2060				94,271
	SSGA TARGET RETIREMENT 2065				26,612
	SSGA TARGET RETIREMENT INCOME				123,938
	Total Collective trust funds				8,074,869

	Futures contracts
	EQUITY FUTURES OFFSET - LONG				(803	)
	FUT MAR 24 EMINI S&P 500				241
	FUT MAR 24 IMMEMINI MDCP				562
	Total Futures contracts				-

	Corporate debt
	AERCAP IRELAND CAP 2.875% DUE 08-14-2024				1,864
	AERCAP IRELAND CAP/GLOBA 1.65% DUE 10-29-2024 BEO				3,088
	AMERN HONDA FIN FLTG RT 1.706417% 06-07-2024				6,604
	APIDOS CLO XXVII / APIDOS CLO XXVII SR SECD NT CL A-1R 144A 6.50814% 07-17-2030				3,245
	BANCO SANTANDER S 2.706% DUE 06-27-2024				2,960
	BANK AMER CORP BANK FLTG RT 02-04-2025				1,099
	BANK OF AMERICA CORPORATION 1.843% 02-04-2025				2,988
	BANK OF NOVIA SCOTIA 2YR FRN NEW ISSUE FLTG RT 03-11-2024				3,002
	BARCLAYS PLC 3.65% DUE 03-16-2025				2,444
	BAXTER INTL INC FLT RT DUE 11-29-2024/06-14-2022 BEO				998
	BOEING CO 1.433% 02-04-2024				2,390
	CAPITAL ONE FINL CORP 05-09-2025				1,999
	CARLYLE GLOBAL MARKET STRATEGI 14/08/2030 0% 08-14-2030				2,510

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Corporate debt - continued
	CHARTER COMMUNICATIONS OPER LLC FRNS 02-01-2024				1,000
	CHASE AUTO OWNER TR 2023-A ASSET BACKED NT CL A-2 144A 5.9% 03-25-2027				3,015
	CIGNA GRP NEW DISC COML PAPER 4/2 YRS 1&2 01-16-2024				7,778
	CONSTELLATION BRANDS INC DISC COML PAPER4/A2 YRS 1&2 01-08-2024				7,688
	CONSTELLATION ENERGY GENERATION LLC DISCCOML PAPER 4/2 YRS 1&2 01-09-2024				7,787
	CREDIT SUISSE AG NEW YORK BRH MEDIUM TER4.75% DUE 08-09-2024 REG				4,969
	DELL EQUIP FIN TR 2021-2 ASSET BACKED NTCL A-3 144A .53% 12-22-2026				413
	DEUTSCHE BK AG N Y BRANCH 3.961% 11-26-2025				1,967
	ELLINGTON FINL MTG TR 2022-1 MTG PASS THRU CTF CL A-1 2.206% 01-25-2067				2,162
	ENERGY TRANSFER L P DISC COML PAPER 4/2 YRS 1&2 01-04-2024				10,690
	ERAC USA FINANCE LLC 01-08-2024				6,490
	FIDELITY NATL INFORMATION SVCS INC DISC COML PAPER 4/2 YRS 1&2 01-05-2024				4,195
	FIDELITY NATL INFORMATION SVCS INC DISC COML PAPER 4/2 YRS 1&2 01-16-2024				2,692
	FORD CR AUTO LEASE TR 2023-B FLTG RT SR 23-B CL A2B 02-15-2026				4,500
	FORD CR AUTO OWNER FLTG RT 6.07864% DUE 08-15-2025				1,236
	GEORGIA PWR CO FLTG RT 05-08-2025				3,007
	GLOBAL PMTS INC 1.5% 11-15-2024				3,857
	GOLDMAN SACHS FLTG RT 6.102014% DUE 12-09-2026				3,365
	GOLDMAN SACHS GROUP INC 5.7% DUE 11-01-2024 BEO				1,904
	GS MTG BACKED SECS 5% DUE 01-25-2052				2,375
	HALEON US CAPITAL LLC 3.024% 03-24-2024				994
	HUMANA INC DISC COML PAPER 4/2 YRS 1&2 01-02-2024				5,798
	HUMANA INC DISC COML PAPER 4/2 YRS 1&2 01-03-2024				1,999
	HYUNDAI AUTO RECEIVABLES TR 2022-C NT CLA-2-B FLTG RATE 6.09864% 11-17-2025				2,062
	INTERCONTINENTAL EXCHANGE INC 4/A2 DISC COML PAPER 01-03-2024				3,098
	INTERCONTINENTAL EXCHANGE INC 4/A2 DISC COML PAPER YRS 1&2 01-05-2024				250
	JPMORGAN CHASE & CO FLTG RT DUE 06-14-2025/06-14-2024 REG				2,003
	KINDER MORGAN INC DISC COML PAPER 4/2 YRS 1&2 01-22-2024				7,372
	L3HARRIS TECHNOLOGIES INC 0% CP 01-16-2023				7,779
	LCM XIII LTD PARTNERSHIP / LCM XIII 0% 07-19-2027				139
	MARATHON STATIC FLTG RT 7.06781% DUE 07-20-2030				2,396
	MFA 2020-NQM2 TR 1.381% DUE 04-25-2065				430
	MIZUHO FINL GROUP INC FLTG 05-22-2026				2,199
	NAVIENT PRIVATE ED LN TR 2020-I 6.43981%04-15-2069				1,410
	NEUBERGER BERMAN CLO LTD 20/04/2031 1.29400002956% 04-21-2031				3,899
	NEXTERA ENERGY CAP HLDGS INC SR NT FLTG RATE 6.371814% 03-21-2024				300
	NOMURA HLDGS INC 2.648% 01-16-2025				1,067
	OBX 2022-NQM1 TR MTG BACKED NT CL A-1 144A 2.30500006676% 11-25-2061				1,999
	OBX 2022-NQM2 TR VAR RT 2.783% DUE 01-25-2062				664
	OSCAR US FDG XIV LLC NT CL A-2 144A 1.6%03-10-2025				26
	PAC GAS & ELEC CO FIXED 3.75% DUE 02-15-2024				199
	PACIFIC GAS & ELEC CO 3.4% 08-15-2024				295
	PVTPL APIDOS CLO 17-26A A1AR FLTG 07-18-2029 USD				1,613
	PVTPL BAMLL COML MTG SECS SR 2019-AHT CL A FLTG 03-15-2034				694
	PVTPL BANK OF AMERICA AUTO TRUST SER 23-2A CL A2 5.85% 08-17-2026				5,029
	PVTPL BAYER US FINANCE LLC BNDS 3.375% 10-08-2024 BEO				3,929
	PVTPL CBAM 2018-8 LTD LLC NT CL A-1 FLTG 3C7 10-20-2029 BEO				2,162
	PVTPL CMO AREIT 2021-CRE5 LTD/AREIT AREIT 2021-C SR NT CL A VAR RT 07-17-2026				1,956
	PVTPL CMO COLT 2021-4 MTG LN TR MTG PASSTHRU CTF CL A-1 10-25-2066				1,847
	PVTPL GOLDEN TREE LN OPPORTUNITIES IX SER 14-9A CL AR2 FLTG 144A 10-29-2029				3,887
	PVTPL GPMT 2021-FL3 LTD/GPMT 2021-FL3 LLC SR SECD NT CL A FLTG 07-16-2035				1,047
	PVTPL HALSEYPOINT CLO II LTD SR 20-2A CL A1 FLTG 07-20-2031				3,389
	PVTPL HYUNDAI AUTO LEASE SECURITIZATION TR 202 FLTG RT SR 23-C CL A2B 03-16-2026				2,401
	PVTPL JACKSON NATIONAL LIFE GLBL FUNDING FLTG RT 06-28-2024				2,605
	PVTPL KKR CLO 9 LTD / KKR CLO 9 LLC 15/07/2030 VAR RT DUE 07-15-2030 BEO				2,035

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Corporate debt - continued
	PVTPL M&T EQUIPTMENT 2023-LEAF1 LLC 5.742% 08-15-2024				1,467
	PVTPL MAGNETITE XVIII LTD/MAGNETITE XVIII LL SR16-18A CL AR2 VAR RT 11-15-2028				163
	PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE LO SR 20-FL4 CL A VAR RT DUE 11-15-2035				1,225
	PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE CO SER 21-FL7 CL A FLTG RT DUE 10-18-2036				3,948
	PVTPL NAVIENT PRIVATE ED REFI LN TR 2021-G CL A 1.58% DUE 04-15-2070 BEO				1,474
	PVTPL NAVIENT PRIVATE ED REFI LN TR SRS 20-HA CL A 1.31% DUE 01-15-2069				835
	PVTPL NAVIENT STUDENT LN TR 2014-1 SR 22-A CL A 2.23% 07-15-2070				1,095
	PVTPL NELNET STUDENT LN TR FLTG RT SER 19-2A CL A 06-27-2067 BEO				1,503
	PVTPL OCTAGON INVT PARTNERS XXI LTD/OCTAGON SR SECD NT 02-14-2031				3,494
	PVTPL PALMER SQUARE LN FDG 2021-3 LTD/SR SECD NT CL A-1 FLTG 5.04257% 07-20-2029				2,034
	PVTPL PALMER SQUARE LOAN FUNDING LTD SER 21-4A CL A1 FLTG RT 10-15-2029 BEO				1,646
	PVTPL SMBC AVIATION CAP FIN DAC 3.55% DUE 04-15-2024				4,369
	PVTPL SOFI CONSUMER LOAN PROGRAM SER 23-15 CL A 5.81% 05-15-2031				749
	PVTPL SOUND PT CLO XVI LTD/SOUND PT CLO XVI VAR RT DUE 07-25-2030 BEO				1,146
	PVTPL STANDARD CHARTERED PLC NT FLTG RATE 11-23-2025				4,576
	PVTPL STRATUS CLO 2021-3 LTD/STRATUS CLO202 SR 21-3A CL A VAR RT DUE 12-29-2029				206
	PVTPL TCW CLO SER 18-1A CL A1R FLTG 04-25-2031 BEO				256
	PVTPL TRILLIUM CR CARD TR II SR 23-3A CLA VAR RT DUE 08-26-2028 BEO				3,211
	PVTPL UBS AG LONDON BRH 09/02/2024 5.72123% DUE 02-09-2024 BEO				700
	PVTPL VENTURE CLO LTD SR 17-28A CL A2R VAR RT 07-20-2030				3,315
	PVTPL VIBRANT CLO VI LTD SER 17-6A CL AR FLTG 06-20-2029				520
	PVTPL VMC FIN 2021-FL4 LLC SR SECD NT CLA 144A FLTG RATE VAR RT DUE 06-16-2036				910
	READY CAP MTG FING FLTG RT 6.43541% DUE 04-25-2038				664
	SARANAC CLO VI LTD / SARANAC CLO VI 6.71659% 08-13-2031				1,808
	SOFI PROFESSIONAL LN PROGRAM 2020-C POSTGRADUATE LN AST BKD NT 1.95% 02-15-2046				989
	SOUND PT CLO XV LTD / SOUND PT CLO SR SECD NT CL A-RR 144A 6.47741% 01-23-2029				606
	SOUTHERN CALIF EDISON CO 1ST & REF MTG FLTG RT 04-01-2024				2,225
	SOUTHERN CALIF EDISON CO DISC COML PAPER4/2 YRS 1&2 01-08-2024				3,494
	SOUTHERN CALIF EDISON CO DISC COML PAPER4/2 YRS 1&2 01-17-2024				1,595
	TOWD PT MTG TR 2021-1 NT CL A1 144A 2.25% 11-25-2061				1,787
	TOYOTA AUTO RECEIVABLES OWNER TRUST SER 22-D CL A2B FLTG RT 01-15-2026				2,348
	TOYOTA LEASE OWNER FLTG RT 5.87407% DUE 04-20-2026				3,400
	V F CORP DISC COML PAPER 4/2 YRS 1&2 01-17-2024				4,486
	VOLKSWAGEN AUTO FLTG RT 5.89407% DUE 01-20-2026				2,402
	VW CR INC DISC COML PAPER 4/2 YRS 1&2 01-05-2024				4,995
	WARNERMEDIA HLDGS INC SR NT NC1 3.788% 03-15-2025				882
	WELLS FARGO & CO 2.406% 10-30-2025				973
	WELLS FARGO & CO MEDIUM TERM SR NTS BOOKVAR RT DUE 04-25-2026/04-25-2025				2,317
	Total Corporate debt				269,066

	Government debt
	GNMA 2016-H17 MTG PASS THRU CTF CL MX FC08-20-2066				457
	GNMA 2016-H20 REMIC PASSTHRU CTF CL MX-PT 09-20-2066				961
	GNMA REMIC PASSTHRU SER 2016-H11 CLS F 05-20-2066				84
	GNMA SR 23-H22 CL FB FLTG RT 09-20-2073				3,021
	UNITED STATES OF AMER TREAS NOTES 3.875%DUE 03-31-2025				7,336
	UNITED STATES OF AMER TREAS NOTES 4.875%DUE 10-31-2028				20,270
	UNITED STATES TREASURY BILLS 04-11-2024				44
	Total Government debt				32,173

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Private 40-Act mutual funds	abc
	PIMCO INTERNATIONAL PORTFOLIO			13,466
	PIMCO INVESTMENT GRADE CREDIT BOND PORTFOLIO			53,462
	PIMCO MUNICIPAL SECTOR PORTFOLIO			2,573
	PIMCO REAL RETURN PORTFOLIO			8,031
	PIMCO U.S. GOVERNMENT SECTOR PORTFOLIO			40,547
	PIMCO EMERGING MARKETS PORTFOLIO			9,285
	PIMCO HIGH YIELD PORTFOLIO			2,309
	PIMCO ASSET-BACKED SECURITIES PORTFOLIO			29,900
	PIMCO MORTGAGE PORTFOLIO			30,103
	PIMCO SHORT-TERM FLOATING NAV PORTFOLIO II			486,796
	Total Private 40-Act mutual funds			676,472

	Other
	BUY TO OPEN REPO W/CITIGROUP 5.39% FROM 12-29-2023 TO 01-02-2024			9,800

		Interest rates 3.00% to 9.75%
	Loans to participants	Maturing 2024 through 2047		94,074

				14,365,877

^*Represents a party-in-interest transaction.

^**Cost information omitted as all investments are fully participant directed.

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ABBOTT LABORATORIES STOCK RETIREMENT PLAN (PUERTO RICO)

DECEMBER 31, 2023 and 2022

C O N T E N T S

Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3

FINANCIAL STATEMENTS

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	5

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	6

NOTES TO FINANCIAL STATEMENTS	7

SUPPLEMENTAL SCHEDULE

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	16

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) as of December 31, 2023 and 2022, the related statement of changes in net assets available for benefits for the year ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for benefits for the year ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

Supplemental information

/s/ GRANT THORNTON LLP

We have served as the Plan’s auditor since 2014.

Chicago, Illinois
June 25, 2024

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2023 and 2022
(Dollars in thousands)


	2023		2022
Assets
Cash	$	-	$	5
Investments, at fair value		217,659		204,193
Notes receivable from participants		5,172		4,359
Due from brokers		16		-
Accrued interest income		54		33

Total assets		222,901		208,590

Liabilities
Cash overdraft		21		-
Accrued expenses		1		-
Due to brokers		3		1

Total liabilities		25		1

NET ASSETS AVAILABLE FOR BENEFITS	$	222,876	$	208,589

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Year ended December 31, 2023
(Dollars in thousands)

Additions
Contributions
Employer	$	2,430
Participant		4,987

Total contributions		7,417

Investment income
Net appreciation in fair value of investments		15,580
Interest and dividends		4,274

Net investment income		19,854

Interest income on notes receivable from participants		233

Net additions		27,504

Deductions
Benefits paid to participants		13,196
Other expenses		21

Total deductions		13,217

NET INCREASE		14,287

Net assets available for benefits
Beginning of year		208,589

End of year	$	222,876

The accompanying notes are an integral part of this statement.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan was established January 1, 2013 in conjunction with Abbott Laboratories (“Abbott”) separating into two publicly traded companies – Abbott and AbbVie Inc. (“AbbVie”). The Plan covers employees of Abbott’s selected subsidiaries and affiliates in Puerto Rico (the “Company”).

The Plan is a profit-sharing plan containing a cash or deferred arrangement intended to qualify for favorable tax treatment under sections 1081.01 (a) and (d) of the Puerto Rico Internal Revenue Code of 2011, as amended. In addition, the Plan provides an arrangement by which employees may invest in Abbott shares. Employees of the Company may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

The Plan’s sponsor is Abbott Healthcare (Puerto Rico) Ltd. Alight Solutions serves as the record keeper of the Plan. The Northern Trust Company (“Custodian”) and Banco Popular de Puerto Rico (“Trustee”) serve as the Plan’s custodian and trustee, respectively. The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

Contributions and Vesting

Contributions to the Plan are paid to a trust administered by the Trustee. An investment committee (the “Committee”) may direct the Trustee to establish investment options of the Committee’s choosing.

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate may contribute from 2% (or 1%, for Abbott Green participants) to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from either pretax earnings or after-tax earnings, or both. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contribution are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options, except for investment options closed to new contributions.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Employer matching contributions to the Plan are made each payroll period based on the participating employees’ eligible earnings. Excluding the Abbott Green participants, the employer contribution for the year ended December 31, 2023 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan. Effective with the first pay period ending after March 1, 2017, employer matching contributions for Abbott Green participants are made at the rate of 100% up to a 3% deferral of eligible earnings. Employer contributions are invested each pay period according to the participant’s investment elections.

In connection with the January 1, 2013 separation of Abbott into two publicly traded companies, Abbott shareholders received as a tax-free distribution one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Plan participants may continue to hold the AbbVie stock they received from the distribution; however, they may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan. AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other investment options available to the participants.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

		Vesting
Service		percentage
Less than two years		0%
Two years or more		100%

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65.

Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in matching contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, (2) pay Plan expenses as deemed appropriate by the Administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2023, approximately $106,400 of forfeitures were used to reduce employer contributions. Forfeitures totaling approximately $118,200 and $113,400 were available at the end of 2023 and 2022, respectively.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Distributions and In-Service Withdrawals

Following retirement, termination or death, participants or their beneficiaries may elect to receive a distribution in installments, a single lump sum or a partial lump sum. Participants may elect a direct rollover of their accounts. Interest, dividends and other earnings will continue to accrue on any deferred amounts prior to distribution.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, are subject to certain limitations.

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to Puerto Rico Internal Revenue Code limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is generally made through periodic payroll deductions or by sending in a payment, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

Investment Valuation

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock and mutual funds - Valued at the published market price per share or unit multiplied by the number of shares or units held.

The following tables summarize the basis used to measure investments at fair value at December 31, 2023 and 2022 (dollars in thousands):

	Basis of Fair Value Measurement
2023	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Common stock	$	95,946	$	-	$	-	$	-	$	95,946
Mutual funds		42,917		-		-		-		42,917
Collective trust funds		-		-		-		76,813		76,813
Private 40-Act mutual funds		-		-		-		1,983		1,983
Total investments at fair value	$	138,863	$	-	$	-	$	78,796	$	217,659

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

	Basis of Fair Value Measurement
2022	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Common stock	$	99,063	$	-	$	-	$	-	$	99,063
Mutual funds		36,775		-		-		-		36,775
Collective trust funds		-		-		-		68,355		68,355
Total investments at fair value	$	135,838	$	-	$	-	$	68,355	$	204,193

	2023
	Fair value (NAV)		Redemption frequency	Redemption notice period	Restrictions
Funds filing as direct filing entity:
Collective trusts	$	76,813	Daily	0 - 5 days	--
Funds not filing as direct filing entity:
Private 40-Act mutual funds
Asset-backed securities		293	Daily	--	Yes (a)
Corporate fixed income		556	Daily	--	Yes (a)
Inflation-indexed bonds		80	Daily	--	Yes (a)
International fixed income		227	Daily	--	Yes (a)
Mortgage-related securities		301	Daily	--	Yes (a)
Municipal fixed income		25	Daily	--	Yes (a)
Short-term fixed income		96	Daily	--	Yes (a)
U.S. Government securities		405	Daily	--	Yes (a)

		1,983
	$	78,796

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

2022

Fair value
(NAV)

Redemption
frequency

Redemption
notice period

Restrictions

Funds filing as direct filing entity:

Collective trusts

68,355

Daily

0 - 5 days

(a)

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie shares. Investment fees for mutual funds and collective trusts are charged against the net assets of the respective fund. The Company pays other record-keeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2023 and 2022 is presented below:

	2023		2022
Abbott common shares, 581,107 and 587,473 shares, respectively (dollars in thousands)	$	63,962	$	64,499
Market value per share	$	110.07	$	109.79

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Custodian. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2023, the Plan received $1,194,000 in common stock dividends from Abbott.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2023 and 2022

NOTE F - TAX STATUS

The Plan received letters dated April 19, 2016 and December 2, 2019 from the Department of the Treasury of the Commonwealth of Puerto Rico that the Plan, as written, qualifies under Section 1081.01(a) of the Puerto Rico Internal Revenue Code of 2011, as amended and, consequently, its enabling trust is exempt from local income tax. The Plan has been amended since receiving the letters. The Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable Puerto Rico Internal Revenue Code.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2023 and 2022, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress.

NOTE G - RISKS AND UNCERTAINTIES

NOTE H – SUBSEQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2023 through the date these financial statements were issued. Management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
EIN: 98-1051267, Plan Number: 002
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
December 31, 2023
(Dollars in thousands)

		(c) Description
		of investment
		including
		maturity date &		(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest	(d) Cost ^**	value
	Common stock - employer securities
*	Abbott Laboratories, common shares			$	63,962

	Common stock
	AbbVie Inc., common stock				31,984
	Total Common stock				95,946

	Mutual funds
	American Funds EuroPacific Growth Fund				5,582
	American Funds The Growth Fund of America Fund				16,152
	American Funds Washington Mutual Investors Fund				3,870
	PIMCO All Asset Fund				2,767
	PIMCO Short Asset Investment Fund				11,029
	Vanguard Mid-Cap Value Index Fund Admiral				3,517
	Total Mutual funds				42,917

	Collective trust funds
	Blackrock International Opportunities Fund				1,994
	GW&K Small-Mid Cap Core Equity Fund				3,154
*	Northern Trust Collective ACWI ex-U.S. Index Fund				801
*	Northern Trust Collective Short Term Investment Fund				294
	SSGA Russell Small/Mid Cap Index Fund				3,919
	SSGA S&P 500 Index Fund				16,394
	SSGA U.S. Bond Index Fund				754
	SSGA Target Retirement 2020				4,181
	SSGA Target Retirement 2025				7,505
	SSGA Target Retirement 2030				10,330
	SSGA Target Retirement 2035				6,572
	SSGA Target Retirement 2040				6,276
	SSGA Target Retirement 2045				4,954
	SSGA Target Retirement 2050				2,863
	SSGA Target Retirement 2055				1,731
	SSGA Target Retirement 2060				536
	SSGA Target Retirement 2065				208
	SSGA Target Retirement Income				4,347
	Total Collective trust funds				76,813

	Private 40-Act mutual funds
	PIMCO Asset-Backed Securities Portfolio				293
	PIMCO Emerging Markets Portfolio				93
	PIMCO High Yield Portfolio				23
	PIMCO International Portfolio				134
	PIMCO Investment Grade Credit Bond Portfolio				533
	PIMCO Mortgage Portfolio				301
	PIMCO Municipal Sector Portfolio				25
	PIMCO Real Return Portfolio				80
	PIMCO Short-Term Floating NAV Portfolio II				96
	PIMCO U.S. Government Sector Portfolio				405
	Total Private 40-Act mutual funds				1,983

		Interest rates 3.25% to 8.50%
*	Loans to participants	Maturing 2024 through 2038			5,172

				$	222,831

^*Represents a party-in-interest transaction.

^**Cost information omitted as all investments are fully participant directed.

EXHIBIT INDEX

Exhibit No.

Exhibit

23.1

Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan.

23.2

Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan (Puerto Rico).

SIGNATURE

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

Date: June 25, 2024
By:

/s/ Sean J. Treacy

Sean J. Treacy

Plan Administrator

Date: June 25, 2024	By:	/s/ Sean J. Treacy
		Sean J. Treacy
		Plan Administrator

Abbott Laboratories Stock Retirement Plan

EIN: 36-0698440, Plan Number: 334

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2023

(Dollars in thousands)